Status:
RECRUITING
Interaction of Volatile Anesthetics With Magnesium
Lead Sponsor:
Christoph Czarnetzki
Collaborating Sponsors:
Centre Hospitalier du Centre du Valais
Ospedale Regionale di Lugano
Conditions:
Neuromuscular Blockade
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Magnesium and volatiles anesthetics both have an effect on the neuromuscular transmission. The primary objective of the study is to quantify the effect of a perfusion of intravenous magnesium on neuro...
Detailed Description
Magnesium sulfate is regularly used during anesthesia, for instance for the reduction of postoperative pain. It reduces the liberation of acetylcholine at the neuromuscular junction. At high plasma co...
Eligibility Criteria
Inclusion
- Patients, age 18 to 65 years inclusive
- American Society of Anesthesiology \[ASA\] status I or II
- Body mass index 19 - 30 kg/m2
- Patient scheduled for elective surgery lasting ≥ 60 minutes
- Patient is able to read and understand the information sheet and to sign and date the consent form.
- Negative urinary or serum pregnancy test (not applicable if status post hysterectomy or tubal ligation or menopausal woman)
Exclusion
- Surgery with need for neuromuscular block
- Contraindication for general anesthesia with laryngeal mask airway, such as gastro-oesophageal reflux.
- Hypersensitivity or allergy to magnesium sulfate or propofol
- Contraindication to volatile anesthetics such as malignant hyperthermia
- Patients with neuromuscular disease
- Patients receiving medications known to influence neuromuscular function (for instance, aminoglycosides or phenytoine)
- Known electrolyte abnormalities (for instance, hypermagnesemia)
- Atrioventricular heart block
- Patients with magnesium treatment within 48 hours before start of study
- Liver insufficiency (bilirubine \<1.5x, ALAT/ASAT\<2.5x the upper limit of normal value)
- Renal insuffisancy (créatinine \<1.5x upper limit of normal value, clearance\<30ml/minute)
- Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial.
- Pregnant or breast-feeding women.
Key Trial Info
Start Date :
November 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT05261516
Start Date
November 18 2022
End Date
August 31 2025
Last Update
May 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Intensive Care, Valais Hospital
Sion, Switzerland, 1951